Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare Biotechnology
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T... see more

Recent & Breaking News (NDAQ:CTXR)

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

PR Newswire April 1, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

PR Newswire February 14, 2025

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

PR Newswire February 6, 2025

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

PR Newswire January 8, 2025

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

PR Newswire January 7, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

PR Newswire December 27, 2024

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

PR Newswire November 25, 2024

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

PR Newswire November 22, 2024

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

PR Newswire November 18, 2024

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

PR Newswire November 15, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR(TM) in Cancer Patients with Recurrent Solid Tumors

PR Newswire November 11, 2024

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire September 5, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR(TM) (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

PR Newswire September 5, 2024

Sidoti Events, LLC's Virtual August Micro-Cap Conference

ACCESS Newswire August 13, 2024

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

PR Newswire August 12, 2024

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

PR Newswire August 12, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

PR Newswire August 12, 2024

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

GlobeNewswire August 9, 2024

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR(TM) (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

PR Newswire August 8, 2024

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

GlobeNewswire August 5, 2024